Abstract:Abstract Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T cells from exhausted status and revive immune response against cancer cells. Based on the immense success in clinical trials, ten α-PD-1 (nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, toripalimab, tislelizumab, zimberelimab, prolgolimab, and dostarlimab) and three α-PD-L1 antibodies (atezolizumab, durvalumab, and avelumab) have been approved for various types of cancers. Nevertheless, the low response rate of α-PD-1/PD-L1 therapy remains to be resolved. For most cancer patients, PD-1/PD-L1 pathway is not the sole speed-limiting factor of antitumor immunity, and it is insufficient to motivate effective antitumor immune response by blocking PD-1/PD-L1 axis. It has been validated that some combination therapies, including α-PD-1/PD-L1 plus chemotherapy, radiotherapy, angiogenesis inhibitors, targeted therapy, other immune checkpoint inhibitors, agonists of the co-stimulatory molecule, stimulator of interferon genes agonists, fecal microbiota transplantation, epigenetic modulators, or metabolic modulators, have superior antitumor efficacies and higher response rates. Moreover, bifunctional or bispecific antibodies containing α-PD-1/PD-L1 moiety also elicited more potent antitumor activity. These combination strategies simultaneously boost multiple processes in cancer-immunity cycle, remove immunosuppressive brakes, and orchestrate an immunosupportive tumor microenvironment. In this review, we summarized the synergistic antitumor efficacies and mechanisms of α-PD-1/PD-L1 in combination with other therapies. Moreover, we focused on the advances of α-PD-1/PD-L1-based immunomodulatory strategies in clinical studies. Given the heterogeneity across patients and cancer types, individualized combination selection could improve the effects of α-PD-1/PD-L1-based immunomodulatory strategies and relieve treatment resistance.

Multi-target Combinatory Strategy to Overcome Tumor Immune Escape

Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?

Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Immune Checkpoint Inhibitor-Based Strategies For Synergistic Cancer Therapy

Next-generation combination approaches for immune checkpoint therapy

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Combination strategies to maximize the benefits of cancer immunotherapy

Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy

Mechanisms of Tumor Resistance to Immune Checkpoint Blockade and Combination Strategies to Overcome Resistance

Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

Emerging immune checkpoint and its combination therapy in cancer treatment

Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment

A “2 + 2” Strategy for Tumor Immune Microenvironment Remodeling Based on Complementary Immune Checkpoint Blockade

Combined Application of Nanotechnology and Multiple Therapies with Tumor Immune Checkpoints

Immune Checkpoint Inhibitors Combined with Targeted Therapy: the Recent Advances and Future Potentials

Overcoming Resistance to Checkpoint Inhibitors with Combination Strategies in the Treatment of Non-Small Cell Lung Cancer

[Immune-checkpoints: the new anti-cancer immunotherapies]

Advances of combined immunotherapy in tumor

Improvement Strategy for Immune Checkpoint Blockade: A Focus on the Combination with Immunogenic Cell Death Inducers.